evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 5 · 71.4%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Overall survival · women with recurrent or FIGO stage IVB cervical cancer

Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).

1 finding from 1 review

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer

Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).

1 finding from 1 review